Latest Market Entry News

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Iondrive Limited confirms strong financial metrics for its proprietary DES battery recycling technology, progressing pilot plant development and divesting exploration assets to sharpen focus on commercialisation.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.

Sprintex Limited has advanced its commercial and technological milestones with major European and Indian orders, breakthrough energy efficiency validation, and a successful A$3.25 million equity raise, positioning the company for accelerated growth.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Alcidion Group Limited reported a robust Q3 FY25 with $13.1 million in cash receipts and a landmark 10-year $37.5 million contract with North Cumbria NHS Trust, prompting an upgrade to its full-year EBITDA guidance.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Smart Parking Limited has reported robust H1 FY25 results, underpinned by a strategic acquisition of Peak Parking LP and a fully underwritten $45 million equity raise to fund its US expansion.

Smart Parking Limited is set to expand its global footprint by acquiring US-based Peak Parking LP for up to USD 36 million, backed by a fully underwritten equity raise and expanded debt facility. The deal promises significant EPS accretion and strategic growth opportunities in the lucrative US parking market.